RCKT

Rocket Pharmaceu

• TipRanks·3d ago

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA)

• Reuters·04/01 12:48

  FDA: ISSUANCE OF A PRIORITY REVIEW VOUCHER TO THE SPONSOR OF A RARE PEDIATRIC DISEASE PRODUCT APPLICATION- FEDERAL REGISTER WEBSITE

• Reuters·04/01 12:48

  FDA: DETERMINED THAT KRESLADI MEETS THE CRITERIA FOR A PRIORITY REVIEW VOUCHER- FEDERAL REGISTER WEBSITE

• NASDAQ·03/30 16:16

  RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

• NASDAQ·03/30 15:47

  Wedbush Reaffirms Rocket Pharma At Outperform With $16 Price Target

• Benzinga·03/30 14:03

  Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday

• Dow Jones·03/30 13:49

  Rocket Pharmaceuticals Is Maintained at Buy by B of A Securities

• Dow Jones·03/30 13:49

  Rocket Pharmaceuticals Price Target Raised to $9.00/Share From $8.00 by B of A Securities

• Benzinga·03/30 13:39

  B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9

• TipRanks·03/30 10:30

  Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

• TipRanks·03/30 10:26

  Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket

• Seeking Alpha·03/29 13:30

  Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited

• TipRanks·03/27 19:15

  Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

• Dow Jones·03/27 18:34

  Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

• Dow Jones·03/27 18:34

  Rocket Pharmaceuticals Price Target Maintained With a $11.00/Share by Chardan Capital